<b>Methods</b>: We searched PubMed, Scopus, and Web of Science in October 2025 for randomized parallel controlled trials that investigated the effect of GLP-1 agonists in patients with MASLD or metabolic-associated steatohepatitis (MASH). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.